Abbott (ABT) stock surges 12% as Q2 earnings beat lifts 2026 EPS outlook to $5.45-$5.60

Abbott Laboratories (NYSE: ABT) shares surged approximately 12% on July 16, 2026 after the healthcare group reported second-quarter adjusted earnings of $1.31 per share and raised its full-year adjusted earnings outlook to between $5.45 and $5.60 per share. Quarterly revenue increased 13% to $12.59 billion, although comparable sales growth was a more measured 4.8% after adjusting for foreign exchange and the contribution from Exact Sciences. Medical Devices delivered 8.4% comparable growth, while the newly consolidated Cancer Diagnostics business helped reported Diagnostics revenue rise 42.3%. The rally put Abbott stock on course for its strongest single-day performance in 24 years and reversed part of a steep year-to-date decline. The central tension is whether this better-than-feared quarter marks a durable earnings acceleration or simply provides temporary relief while Abbott integrates Exact Sciences and tries to revive its Nutrition business.

Why did Abbott Laboratories stock record its strongest advance in 24 years after Q2 earnings?

Abbott’s results exceeded market expectations on both revenue and adjusted earnings, but the scale of the stock reaction went well beyond the size of the numerical beat. Adjusted earnings of $1.31 per share were three cents above the widely followed consensus estimate, while revenue of $12.59 billion was modestly ahead of expectations near $12.5 billion.

The company also lifted the lower and upper ends of its adjusted earnings guidance. Abbott previously expected adjusted earnings of $5.38 to $5.58 per share and now forecasts $5.45 to $5.60. The midpoint increased from $5.48 to approximately $5.53, an improvement of less than 1%.

A roughly 12% share-price gain in response to a sub-1% midpoint guidance increase indicates that the market was reacting to more than the arithmetic. Abbott entered the results carrying concerns about slower medical procedure volumes, weaker Nutrition sales, the financial burden created by the Exact Sciences acquisition and the possibility that its 2026 growth expectations were too ambitious.

The quarter reduced several of those concerns simultaneously. Medical Devices remained resilient, Cancer Diagnostics delivered double-digit comparable growth, Nutrition improved sequentially and management maintained its 6.5% to 7.5% full-year comparable sales growth forecast.

The market response therefore represented a reassessment of downside risk. Abbott did not suddenly become a faster-growing company because of a three-cent earnings beat. Instead, the quarter offered evidence that the operating environment and integration process were holding up better than the depressed share price had implied.

The rally also spread across the medical-device industry. Boston Scientific Corporation, Stryker Corporation and Medtronic plc all traded higher as Abbott’s performance eased broader concerns about procedure volumes and healthcare insurance coverage.

How much of Abbott’s 13% revenue growth came from Exact Sciences rather than legacy businesses?

Abbott’s 13% reported revenue growth requires careful interpretation because it includes the consolidation of Exact Sciences, which Abbott acquired on March 23, 2026. Comparable sales growth, which includes equivalent historical Exact Sciences revenue and removes foreign-exchange effects, was 4.8%.

That gap does not undermine the result, but it changes the analytical conclusion. Reported growth shows how much larger Abbott has become following the transaction. Comparable growth provides the clearer indication of how the combined portfolio performed against the corresponding prior-year businesses.

Abbott generated $5.22 billion of second-quarter revenue in the United States, up 22% on a reported basis but 3.5% on a comparable basis. International revenue increased 7.5% to $7.38 billion, with comparable growth of 5.8%.

Diagnostics produced the largest difference between reported and comparable growth. Segment revenue reached $3.09 billion, an increase of 42.3% as reported but only 2.9% on a comparable basis.

Cancer Diagnostics, which now contains the former Exact Sciences operations, generated $919 million of quarterly revenue and grew 13.3% on a comparable basis. Abbott said Cologuard benefited from mid-teens growth supported by both new and repeat users, while precision oncology and international operations also contributed.

Core Laboratory Diagnostics generated $1.42 billion and grew 3.2% on a comparable basis. Rapid and Molecular Diagnostics revenue fell 8% on the same basis to $755 million as lower respiratory-virus testing demand continued to weigh on the business.

The Exact Sciences contribution is therefore substantial, but the acquisition is not merely creating accounting growth through consolidation. Cancer Diagnostics produced an underlying double-digit expansion rate, which is the type of performance Abbott needs if the transaction is to improve its long-term growth profile.

Why does Abbott’s higher 2026 EPS outlook matter despite a relatively modest midpoint increase?

The raised guidance matters because Abbott has maintained its earnings trajectory while absorbing approximately $0.20 per share of expected dilution from Exact Sciences in 2026. The acquisition increases revenue immediately, but financing costs, integration expenses and acquired intangible amortisation create near-term pressure on earnings.

Abbott expects third-quarter adjusted earnings of $1.38 to $1.46 per share. The midpoint of $1.42 is broadly aligned with prevailing expectations, suggesting that management is not relying on an unusually aggressive third-quarter assumption to support the full-year forecast.

The more demanding target is Abbott’s reaffirmed comparable sales growth range of 6.5% to 7.5%. Comparable growth was 3.7% in the first quarter, 4.8% in the second quarter and approximately 4.3% across the first half.

Reaching the full-year range will require a material acceleration during the second half. Management expects stronger Nutrition trends, continued Medical Devices growth and further contribution from Cancer Diagnostics to provide that improvement.

Adjusted gross margin strengthened to approximately 58% of sales during the second quarter, compared with roughly 57% in the prior-year period. That expansion helped offset higher research, commercial and financing expenses and provides a clearer explanation for why Abbott could raise earnings guidance despite comparable sales growth remaining below its full-year target.

The guidance increase should therefore be read as a vote of confidence in second-half operating leverage. If Abbott delivers faster comparable growth while maintaining the stronger adjusted margin, the higher earnings range may prove achievable. If Nutrition recovery stalls or Medical Devices slows, the company will have less room to absorb integration and financing costs.

What did Medical Devices reveal about procedure demand, diabetes care and cardiovascular growth?

Medical Devices remained Abbott’s largest business, producing second-quarter sales of $5.85 billion. Revenue increased 9% on a reported basis and 8.4% on a comparable basis, with U.S. comparable growth of 8% and international growth of 8.7%.

The result was important because investors had become increasingly concerned that softer hospital procedure volumes and changes in insurance coverage could weaken demand for cardiovascular and other medical technologies. Abbott’s performance showed limited evidence of a broad deterioration during the quarter.

Electrophysiology revenue increased 13.4% on a comparable basis to $861 million, making it one of the strongest parts of the portfolio. Rhythm Management grew 9.5% to $743 million, while Heart Failure increased 8.7% to $401 million.

The performance also reflected ongoing product launches. Abbott began a limited United States launch of its next-generation Volt pulsed-field ablation catheter in May and expects to move towards a full market release during the third quarter. International adoption of Volt and TactiFlex Duo also supported the electrophysiology franchise.

Diabetes Care remained the largest individual Medical Devices category, generating $2.19 billion of sales. The business grew 10.5% on a reported basis and 9% on a comparable basis, while continuous glucose-monitor sales increased 9.5% on a comparable basis.

Abbott received European regulatory clearance in May for Libre Duo, a dual glucose and ketone wearable sensor. The company plans to begin an international rollout during the autumn, with a United States launch dependent on Food and Drug Administration approval.

Other divisions were less dynamic. Structural Heart comparable growth was 5.7%, Vascular grew 5.1% and Neuromodulation increased only 1.2%. Those figures do not threaten the overall Medical Devices trajectory, but they underline the increasing importance of electrophysiology, rhythm management and diabetes care in sustaining high-single-digit segment growth.

Is Exact Sciences strengthening Abbott’s diagnostics portfolio quickly enough to justify the debt burden?

Abbott completed its acquisition of Exact Sciences for approximately $20.6 billion on March 23, 2026. The transaction was financed primarily through $20 billion of newly issued long-term debt, with the remainder funded from existing cash.

Abbott also assumed approximately $2.8 billion of Exact Sciences debt. It repaid $1.4 billion during March and previously indicated that the remaining assumed debt would be repaid during 2026.

The acquisition provides Abbott with Cologuard for colorectal cancer screening, Oncotype DX for treatment decisions in breast cancer, Oncodetect for molecular residual disease testing and Cancerguard for multi-cancer early detection. It creates a dedicated Cancer Diagnostics business and gives Abbott exposure to faster-growing screening and precision-oncology markets.

The second-quarter performance was encouraging because Cancer Diagnostics delivered 13.3% comparable growth. That growth helps demonstrate why Abbott was prepared to accept near-term earnings dilution and a significantly larger debt burden.

The financing consequences are nevertheless visible. Abbott’s second-quarter net interest expense increased to $299 million from $50 million a year earlier. That increase represents a recurring cost that the acquired business must overcome before the transaction can create incremental earnings value.

The acquisition also contributed to higher amortisation, integration and commercial expenses. Abbott’s intangible amortisation expense increased to $658 million from $420 million, while selling, general and administrative spending rose 30.3% to $4.03 billion.

The transaction thesis will ultimately depend on Abbott maintaining double-digit Cancer Diagnostics growth, expanding Exact Sciences products internationally, improving margins and reducing acquisition-related leverage. One quarter of strong Cologuard performance is encouraging, but it does not complete that proof cycle.

William Blair indicated that the Cancer Diagnostics results should improve sentiment towards the acquisition, while J.P. Morgan viewed Abbott as capable of sustaining growth within a more mature continuous glucose-monitoring market. The next several quarters must convert that improved sentiment into recurring earnings and cash flow.

Can Nutrition recover while Established Pharmaceuticals and emerging markets sustain momentum?

Nutrition remained the weak point in Abbott’s portfolio. Second-quarter sales fell 3.1% to $2.14 billion on a reported basis and declined 3.6% on a comparable basis.

United States Nutrition revenue fell 9%, including a 10.7% decline in Pediatric Nutrition and a 6.4% decline in Adult Nutrition. International Pediatric Nutrition performed better, growing 6.4% on a comparable basis, while international Adult Nutrition declined 2.8%.

Abbott attributed the overall reduction to lower volumes and strategic pricing actions implemented during the fourth quarter of 2025. The more encouraging signal was sequential improvement. Nutrition revenue increased by $127 million from the first quarter as pricing, new products and improving consumption trends began to support the business.

Management said recent United States Women, Infants and Children contract gains were contributing to the Pediatric Nutrition run rate. New Ensure formulations with higher protein and lower sugar were also intended to improve the Adult Nutrition portfolio.

A sequential recovery is not the same as a completed turnaround. Abbott must show that the improved quarterly run rate can produce positive year-over-year growth without sacrificing the margin benefits of its earlier pricing decisions.

Established Pharmaceuticals provided a useful counterweight. Sales increased 8.4% to $1.50 billion on a reported basis and 8.7% on a comparable basis. Key Emerging Markets generated $1.16 billion and grew 10.7% comparably, supported by double-digit growth across several Latin American and Asia-Pacific countries.

This diversification matters because Abbott does not depend on one product or geography for growth. Medical Devices, Cancer Diagnostics and emerging-market branded pharmaceuticals can offset temporary weakness elsewhere. However, delivering the upper half of the 2026 sales outlook will be much easier if Nutrition becomes a contributor rather than a continuing drag.

Why did GAAP earnings fall sharply even as Abbott raised its adjusted profit forecast?

Abbott’s GAAP net earnings fell 47.8% to $928 million, while diluted GAAP earnings declined to $0.53 per share from $1.01. Operating earnings decreased 17.5% to $1.69 billion despite the double-digit increase in reported revenue.

The decline primarily reflected higher intangible amortisation, acquisition expenses, legal reserves, investment impairments, financing costs and tax adjustments. Abbott excluded $1.36 billion of net after-tax specified charges, equal to $0.78 per share, when calculating its adjusted results.

Adjusted net earnings increased 3.5% to $2.29 billion, while adjusted diluted earnings per share rose 4% to $1.31. The difference between the GAAP and adjusted figures has therefore widened materially following Exact Sciences.

Some of that gap is expected following a large acquisition because accounting rules require acquired intangible assets to be amortised. However, investors should still monitor the composition and duration of adjustments. Integration costs may decline, while amortisation and the higher interest burden will remain for longer.

Abbott also returned $2.1 billion to shareholders through dividends and share repurchases during the quarter. That reflects management’s confidence in the group’s cash-generating capacity, but capital returns must now be balanced against debt reduction, integration spending and continued investment in product development.

The company’s adjusted results provide a clearer picture of ongoing operations, but the GAAP numbers remain relevant when assessing the total financial cost of the Exact Sciences transaction.

What does Abbott’s 12% share-price surge change about the risk-reward picture for ABT investors?

Abbott shares traded near $100 following the results, compared with the previous close near $89.30. That left the stock approximately 6% above its July 10 close and about 10% higher than its June 16 close.

Even after the rally, Abbott remained roughly 20% below its level at the start of 2026 and approximately 27% beneath its 52-week high of $137.49. The stock was around 22% above its 52-week low of $81.97.

The movement therefore represents a powerful rebound from depressed expectations rather than a return to previous valuation highs. At approximately $100 per share and 1.74 billion shares outstanding, Abbott’s implied market capitalisation was close to $174 billion.

Using the midpoint of the new adjusted earnings guidance, the shares were valued at approximately 18 times expected 2026 adjusted earnings. Before the announcement, the same midpoint implied a multiple close to 16 times.

That valuation expansion means part of the better outlook has already been priced in. Further upside would likely require Abbott to deliver the second-half sales acceleration, maintain high-single-digit Medical Devices growth and show that Exact Sciences can expand without creating additional earnings dilution.

The share-price response is positive evidence of improved institutional sentiment, but it also raises the execution threshold. A company trading near $100 after a 12% rally will receive less tolerance for a third-quarter miss than it would have received near its recent lows.

Which third-quarter milestones will determine whether Abbott can sustain its earnings-driven rerating?

The third quarter will test whether the second-quarter rebound was the beginning of a stronger earnings cycle. Abbott’s adjusted earnings target of $1.38 to $1.46 per share provides the first measurable benchmark.

Comparable sales growth must accelerate materially if the company is to reach its full-year target of 6.5% to 7.5%. Continued double-digit growth in Cancer Diagnostics and electrophysiology will be important, but Nutrition must also move closer to positive growth.

The full United States rollout of the next-generation Volt pulsed-field ablation catheter could strengthen cardiovascular-device momentum. The planned international introduction of Libre Duo provides another potential catalyst, while regulatory progress for the Amulet 360 left atrial appendage device could support the Structural Heart pipeline.

Investors will also need evidence that integration spending and acquisition-related adjustments are beginning to moderate. Interest expense will remain elevated, making revenue growth, adjusted margin expansion and cash generation increasingly important.

Abbott improved the investment case by beating expectations, raising guidance and demonstrating resilience in its largest operating division. What remains unresolved is whether the combined company can accelerate comparable growth enough to absorb Exact Sciences dilution, restore Nutrition and justify the higher post-earnings valuation. The third-quarter combination of sales growth, adjusted margin and Cancer Diagnostics performance will provide the next decisive test.

What are the key takeaways from Abbott’s Q2 earnings and raised 2026 EPS outlook?

• Abbott Laboratories reported second-quarter revenue of $12.59 billion, representing 13% reported growth and 4.8% comparable growth.
• Adjusted diluted earnings increased 4% to $1.31 per share, exceeding prevailing market expectations.
• Abbott raised its full-year adjusted earnings guidance from $5.38-$5.58 to $5.45-$5.60 per share.
• The company maintained its 6.5% to 7.5% comparable sales growth forecast despite first-half comparable growth of approximately 4.3%.
• Medical Devices generated $5.85 billion of revenue and grew 8.4% comparably, led by electrophysiology, rhythm management, heart failure and diabetes care.
• Diagnostics reported 42.3% growth following the Exact Sciences acquisition, but underlying comparable growth was 2.9%.
• Cancer Diagnostics grew 13.3% on a comparable basis, providing early support for Abbott’s $20.6 billion acquisition strategy.
• Nutrition remained the weakest division with a 3.6% comparable decline, although sales improved by $127 million from the first quarter.
• GAAP net earnings fell 47.8% because of acquisition-related charges, amortisation, financing costs, legal reserves, impairments and tax adjustments.
• Abbott shares surged approximately 12%, putting the stock on course for its largest daily gain in 24 years, although it remained substantially below its 52-week high.